Results 21 to 30 of about 23,315 (198)

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

Journal of Lipid Research, 2010
Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and ...
Lin-Hua Zhang, Vaijinath S. Kamanna, Shobha H. Ganji, Xi-Ming Xiong, Moti L. Kashyap   +4 more
doaj   +1 more source

Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats

Frontiers in Pharmacology, 2017
Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.
Li Sun, Quan Yuan, Tianhua Xu, Li Yao, Jiangmin Feng, Jianfei Ma, Lining Wang, Changlong Lu, Danan Wang   +8 more
doaj   +1 more source

Current clinical evidence on pioglitazone pharmacogenomics

Frontiers in Pharmacology, 2013
Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ).
Marina eKawaguchi-Suzuki, Reginald F. Frye   +1 more
doaj   +1 more source

Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. [PDF]

PLoS ONE, 2014
Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced
Akinobu Ochi, Katsuhito Mori, Masanori Emoto, Shinya Nakatani, Tomoaki Morioka, Koka Motoyama, Shinya Fukumoto, Yasuo Imanishi, Hidenori Koyama, Eiji Ishimura, Masaaki Inaba   +10 more
doaj   +1 more source

Effects of Pioglitazone on Stearoyl-CoA Desaturase in Obese Zucker fa/fa Rats

Journal of Pharmacological Sciences, 2007
The effects of a peroxisome proliferator activated receptor γ (PPARγ) agonist on hepatic stearoyl-CoA desaturase (SCD) in insulin-resistant and obese Zucker fa/fa rats were studied.
Tomoaki Toyama, Naomi Kudo, Yasuhide Hibino, Atsushi Mitsumoto, Masazumi Nishikawa, Yoichi Kawashima   +5 more
doaj   +1 more source

The Effect of Co-administration of Pioglitazone and Simvastatin on Insulin Resistance Parameters and PPAR.γ Expression in Insulin-resistant Rats [PDF]

Journal of Kerman University of Medical Sciences, 2017
Backgrounds: Insulin resistance is a pathological condition associated with metabolic syndrome. In this condition, insulin action in liver, muscles, and adipocytes decreases which leads to hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Gholam Abbas Mohammadi, Behnaz Danesh, Hosein Fallah, Samaneh Rahemi   +3 more
doaj  

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Cardiovascular Diabetology, 2017
Background and aims Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary ...
Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren, Jan Westerink   +4 more
doaj   +1 more source

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim   +16 more
doaj   +1 more source

Lilrb4a Suppression Reprograms Microglia to Mitigate APOE4‐Associated Amyloid Plaques and Cerebral Amyloid Angiopathy in Association With a PPAR‐Linked Pro‐Clearance State

Advanced Science, EarlyView.
Targeting Lilrb4a in Apolipoprotein E4 (APOE4)‐associated Alzheimer's disease (AD) reprograms microglia toward a beneficial, phagocytic state. Genetic deletion or antisense inhibition of Lilrb4a suppresses p‐SHP2/NF‐κB/STAT1 signaling, restores PPAR‐linked lipid and energy metabolism, and reduces amyloid plaque burden and cerebral amyloid angiopathy ...
Changxu Nie, Ruixi Yang, Xiaotong Wang, Ping Jia, Xueqi Zhang, Yaqi Dai, Xue Bai, Sijia Duan, Yufeng Li, Peng Zheng, Xin Tian, Li Jiang, Chao Wang   +12 more
wiley   +1 more source

Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan

Emergency Medicine International, 2021
Background. Pioglitazone use via the PPARγ agonist in sepsis patients is inconclusive. It was based on a great number of animal studies. However, except for information from animal studies, there are merely any data of human studies for reference ...
Ming-Shun Hsieh, Sung-Yuan Hu, Shu-Hui Liao, Chia-Ming Chang, Vivian Chia-Rong Hsieh, Chorng-Kuang How   +5 more
doaj   +1 more source